Related Experiment Video
Updated: Jul 1, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Dissociation of activated protein C functions by elimination of protein S cofactor enhancement
Shona Harmon1, Roger J S Preston, Fionnuala Ni Ainle
1Haemostasis Research Group, Institute of Molecular Medicine, St James's Hospital, Trinity College, Dublin 8, Ireland.
Insights
Activated protein C (APC) is crucial for blood clotting and cell protection. Researchers found a specific mutation (L38D) that separates APC's anticoagulant and cell-protective functions, offering potential therapeutic benefits.
Area of Science:
- Biochemistry
- Molecular Biology
- Hematology
Background:
- Activated protein C (APC) has dual roles: anticoagulation by inactivating factors Va and VIIIa, and cytoprotection via PAR-1 signaling.
- Protein S is a key cofactor for APC's anticoagulant function but its role in cytoprotective signaling is unknown.
Purpose of the Study:
- To investigate the role of the APC Gla domain in protein S binding and function.
- To characterize the impact of specific mutations on APC's anticoagulant and cytoprotective activities.
Main Methods:
- Site-directed mutagenesis was used to create APC variants with amino acid substitutions in the Gla domain.
- Assays were performed using purified proteins and plasma to measure Factor Va proteolysis and PAR-1 signaling.
Main Results:
- Mutations D35T, D36A, and A39V showed mild impairment of protein S-dependent anticoagulant activity but normal cytoprotective activity.
- The L38D mutation completely abolished protein S cofactor function, resulting in minimal anticoagulant activity.
- APC-L38D retained normal interaction with the endothelial cell protein C receptor and PAR-1 signaling.
Conclusions:
- Eliminating protein S cofactor enhancement of APC's anticoagulant function effectively separates its dual roles.
- This separation offers a novel strategy for developing therapeutic applications of APC.
Abstract:
Activated protein C (APC) plays a critical anticoagulant role in vivo by inactivating procoagulant factor Va and factor VIIIa and thus down-regulating thrombin generation. In addition, APC bound to the endothelial cell protein C receptor can initiate protease-activated receptor-1 (PAR-1)-mediated cytoprotective signaling. Protein S constitutes a critical cofactor for the anticoagulant function of APC but is not known to be involved in regulating APC-mediated protective PAR-1 signaling. In this study we utilized a site-directed mutagenesis strategy to characterize a putative protein S binding region within the APC Gla domain. Three single amino acid substitutions within the APC Gla domain (D35T, D36A, and A39V) were found to mildly impair protein S-dependent anticoagulant activity (<2-fold) but retained entirely normal cytoprotective activity. However, a single amino acid substitution (L38D) ablated the ability of protein S to function as a cofactor for this APC variant. Consequently, in assays of protein S-dependent factor Va proteolysis using purified proteins or in the plasma milieu, APC-L38D variant exhibited minimal residual anticoagulant activity compared with wild type APC. Despite the location of Leu-38 in the Gla domain, APC-L38D interacted normally with endothelial cell protein C receptor and retained its ability to trigger PAR-1 mediated cytoprotective signaling in a manner indistinguishable from that of wild type APC. Consequently, elimination of protein S cofactor enhancement of APC anticoagulant function represents a novel and effective strategy by which to separate the anticoagulant and cytoprotective functions of APC for potential therapeutic gain.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Clot Retraction and Fibrinolysis
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Complement System
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

